B
Bull
Bull · 25%ITOS
$11.00
Precio del escenario
$10.150
+0.020 (+0.20%)Al cierre
Loading chart…
- High
- 10.170
- Open
- 10.140
- VWAP
- 10.15
- Vol
- 11.01M
- Mkt Cap
- 559.91M
- Low
- 10.140
- Amount
- 111.76M
- EV/EBITDA, TTM
- 1.20
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Métricas de valoración
The current forward P/E ratio for Iteos Therapeutics Inc (ITOS) is -1.73, compared to its 5-year average forward P/E of -79.05.
Alphio AI Price Scenarios for ITOS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
5.006-30NewsfilterMuna Therapeutics Announces CEO Transition and Strategic Focus
8.509-05Globenewswire$HAREHOLDER NOTICE: M&A Class Action Firm Ongoing Investigation into the Merger of MTWO, ITOS, DYNX, and PHLT
7.008-20PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
7.008-19GlobenewswireInvestor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in iTeos Therapeutics, Inc. Sale - ITOS
4.008-07BenzingaWells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11
ITOS FAQ — answered by Alphio AI
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.